{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:13:06Z","timestamp":1760292786985,"version":"build-2065373602"},"reference-count":53,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2006,11,17]],"date-time":"2006-11-17T00:00:00Z","timestamp":1163721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin \u03b1 (DA) is an erythropoiesis\u2010stimulating protein (ESP) that is more highly glycosylated and has a longer half\u2010life relative to recombinant human erythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once\u2010weekly, subcutaneous DA (75\u2013300 \u03bcg) for 16 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Fifty\u2010five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO\u2010naive patients and 45.7% rHuEPO\u2010treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38\u201387 years), the median age at the initiation of DA treatment was 75 years (range, 39\u201391 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0\u2013159.0 weeks; &lt;1 week in 53.1% of patients). According to the French\u2010American\u2010British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low\u2010risk group, and 36.2% of patients were in the intermediate\u20101\u2010risk group. The median baseline hemoglobin level was 8.9 g\/dL (range, 8.4\u20139.1 g\/dL). The Starting DA dose was 75 \u03bcg per week in 3.7% of patients, 150 \u03bcg per week in 65.4% of patients, and 300 \u03bcg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony\u2010stimulating factors. No DA\u2010related adverse reactions occurred.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.22343","type":"journal-article","created":{"date-parts":[[2006,11,17]],"date-time":"2006-11-17T18:32:55Z","timestamp":1163788375000},"page":"2807-2816","source":"Crossref","is-referenced-by-count":25,"title":["Darbepoetin \u03b1 for the treatment of anemia in patients with myelodysplastic syndromes"],"prefix":"10.1002","volume":"107","author":[{"given":"Pilar","family":"Giraldo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benet","family":"Nomdedeu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Loscertales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Requena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"de Paz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Tormo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Benedit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Gasquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Aranesp in Myelodysplastic Syndromes (ARM) Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,12,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.1.104"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199905273402107"},{"key":"e_1_2_6_4_2","unstructured":"The Myelodysplastic Syndromes Foundation. Available at URL:http:\/\/www.mds\u2010foundation.org. Accessed July 15 2006."},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb06430.x"},{"key":"e_1_2_6_6_2","first-page":"905","article-title":"No increase in age\u2010specific incidence of myelodysplastic syndromes","volume":"89","author":"Germing U","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(97)00159-8"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.354"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb06733.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1995.tb00206.x"},{"key":"e_1_2_6_11_2","first-page":"1197","article-title":"Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994\u20131998","volume":"88","author":"Iglesias Gallego M","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(02)00098-X"},{"key":"e_1_2_6_13_2","first-page":"9","article-title":"Detection of risk groups in myelodysplastic syndromes. A multicenter study","volume":"87","author":"Belli C","year":"2002","journal-title":"Haematologica."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp048266"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"e_1_2_6_16_2","first-page":"1716","article-title":"A type II mutation (Glu 117 stop) induction of allele\u2010specific MRNA degradation and factor XI deficiency","volume":"90","author":"Malcovati L","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_6_19_2","first-page":"E3","article-title":"Supportive care including growth factors in myelodysplastic syndromes","volume":"8","author":"Gardin C","year":"2004","journal-title":"Rev Clin Exp Hematol."},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-004-0961-9"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2004.16.Supplement-1.112"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.10"},{"key":"e_1_2_6_23_2","first-page":"1209","article-title":"Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients","volume":"87","author":"Beguin Y","year":"2002","journal-title":"Haematologica."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.1038"},{"key":"e_1_2_6_25_2","first-page":"434","article-title":"Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy","volume":"81","author":"Cazzola M","year":"1996","journal-title":"Haematologica."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01085.x"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.4013211.x"},{"key":"e_1_2_6_28_2","first-page":"733","article-title":"Response to recombinant human erythropoietin in patients with myelodysplastic syndromes","volume":"3","author":"Stasi R","year":"1997","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb08421.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03583.x"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01530.x"},{"key":"e_1_2_6_32_2","first-page":"435","article-title":"Human recombinant erythropoietin in the treatment of myelodysplastic syndromes anemia. Meta\u2010analytic study [in Spanish]","volume":"39","author":"Rodriguez JN","year":"1994","journal-title":"Sangre (Barcelona)."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(91)90025-O"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1578"},{"issue":"2","key":"e_1_2_6_35_2","first-page":"S19","article-title":"Pretreatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients","volume":"21","year":"2005","journal-title":"Curr Med Res Opin."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-1-99"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.3.3.501"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi400"},{"key":"e_1_2_6_39_2","doi-asserted-by":"crossref","first-page":"24a","DOI":"10.1182\/blood.V104.11.69.69","article-title":"High response rate to darbepoetin alfa in \u201clow risk\u201d MDS: results of a phase II study [abstract]","volume":"104","author":"Mannone L","year":"2004","journal-title":"Blood."},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05288.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"713a","DOI":"10.1182\/blood.V106.11.2541.2541","article-title":"A phase 2, single\u2010arm, open\u2010label trial to evaluate the effectiveness of darbepoetin alfa for the treatment of anemia in patients with low\u2010risk myelodysplastic syndrome","volume":"106","author":"Gabrilove J","year":"2005","journal-title":"Blood."},{"key":"e_1_2_6_42_2","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson BD","year":"2000","journal-title":"Blood."},{"key":"e_1_2_6_43_2","first-page":"419","article-title":"A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome","volume":"3","author":"Patton JF","year":"2005","journal-title":"J Support Oncol."},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1G042"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04153.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2005.1.161"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3872"},{"key":"e_1_2_6_48_2","first-page":"MS4","volume-title":"Myelodysplastic Syndromes. NCCN Practice Guidelines in Oncology","author":"National Comprehensive Cancer Network, Inc.","year":"2006"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03907.x"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-0044-6"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.10.4076.bloodjournal87104076"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.1.68.413k23_68_75"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02016.x"},{"key":"e_1_2_6_54_2","first-page":"1058","article-title":"Erythropoietin plus granulocyte colony\u2010stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders","volume":"84","author":"Remacha AF","year":"1999","journal-title":"Haematologica."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.22343","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.22343","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:38:37Z","timestamp":1760290717000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.22343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12,8]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12,15]]}},"alternative-id":["10.1002\/cncr.22343"],"URL":"https:\/\/doi.org\/10.1002\/cncr.22343","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2006,12,8]]}}}